Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Spinal Muscular Atrophy Market Growth Performance Trended Historically, And What Lies Ahead?

In recent years, we have observed a brisk expansion in the spinal muscular atrophy market size. From $3.53 billion in 2024, it is expected to scale up to $4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.3%. The notable growth during the previous period is a result of factors such as enhanced diagnostic capabilities and early detection, rising incidences of rare genetic diseases, improvements in healthcare infrastructure, support from government and regulatory bodies, and a surge in unfulfilled healthcare needs.

The market for spinal muscular atrophy is predicted to experience swift expansion in the coming years, ballooning to$6.53 billion by 2029″ at a CAGR of 13.0%. The anticipated growth in this period can be credited to elements such as heightened awareness and diagnosis level, broadening treatment opportunities, an increase in health care investments in rare diseases, a supportive regulatory atmosphere, and a rise in health care expenditure. Key trends during this forecast period are expected to be the evolution in oral treatments, acceptance of gene therapy, advancements in drug delivery systems, the integration of artificial intelligence in the development of SMA treatments, and advancements in gene editing technologies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theSpinal Muscular Atrophy Market?

The increase in rare genetic diseases is anticipated to boost the spinal muscular atrophy market in the future. These rare genetic diseases, which are caused by gene mutations and impact a tiny proportion of the population, often lead to serious, long-term health issues. The heightened incidence of such diseases is due to advancements in diagnostic techniques, greater awareness, and easier access to genetic testing, contributing to more cases being discovered and reported. Spinal muscular atrophy (SMA) provides a clear example of the issues and potential in learning about hereditary diseases, underlining the need to further research into genetic conditions. For example, a report from the Office for National Statistics, a United Kingdom government agency, in July 2023, indicated that SMN1 genetic testing has facilitated accurate epidemiological studies. These studies revealed that SMA appears in 1 of every 10,000 to 20,000 live births and that over 95% of the patients afflicted are homozygous for SMN1 deletion. As a result, the increasing prevalence of rare genetic diseases is expected to fuel the growth of the spinal muscular atrophy market.

Which Segments in the Spinal Muscular Atrophy Offer the Most Growth?

The spinal muscular atrophymarket covered in this report is segmented –

1) By Type: Type 1 (Severe); Type 2 (Intermediate); Type 3 (Mild); Type 4 (Adult)

2) By Age: Pediatric; Adults

3) By Treatment: Drug Therapy; Gene Therapy

4) By End User: Hospital pharmacy; Online pharmacy; Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA; Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA; Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA; Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA; Late-Onset SMA

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp

What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theSpinal Muscular Atrophy Market?# Market?

North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Spinal Muscular Atrophy Industry?

Several large firms in the spinal muscular atrophy market are creating unique products like dry syrup to boost medication adherence and make administering medicine easier for pediatric patients and others facing difficulties swallowing. Dry syrup, a medicinal powder that is mixed with water before ingestion, is usually given to children and patients who struggle to swallow tablets or capsules. For example, in September 2024, Japan’s Chugai Pharmaceutical Co., Ltd. attained regulatory approval from the Ministry of Health, Labour and Welfare of Japan for the extended use of its drug, Evrysdi (risdiplam). The approval enables its administration to pre-symptomatic spinal muscular atrophy (SMA) patients and those under two months of age. This crucial step allows for earlier treatment before the onset of symptoms, possibly improving the therapeutic results for affected infants. The decision was backed by the RAINBOWFISH study data, which evaluated Evrysdi’s safety and effectiveness in SMA-diagnosed infants not yet showing symptoms. Results revealed that infants treated with Evrysdi reached developmental milestones like unaided sitting and enhanced motor skills within 12 months. This highlights the potential of the drug to alter the course of the disease if given early.

View the full report here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

What Are the Key Elements That Define the Spinal Muscular Atrophy Market?

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized by the progressive loss of motor neurons in the spinal cord, leading to muscle weakness and atrophy. It is caused by mutations in the SMN1 gene, resulting in insufficient survival motor neuron (SMN) protein. SMA affects voluntary muscle movements, particularly those involved in walking, swallowing, and breathing.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20965

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model